Promising Evidence of New Drug Therapies in Lethal Lung Disease
Lethal lung disease
Several promising new treatments may prolong lives as well as improve the quality of life for people living with pulmonary arterial hypertension. Research showing benefits of these novel drug therapies for lethal lung disease will be discussed today at the 26th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT).
Pulmonary arterial hypertension (PAH), high blood pressure in the pulmonary arteries in the lungs, is a life-threatening disease. Therapeutic options have, until recently, been limited and many patients with PAH faced lung transplantation. In recent years, research has identified a number of novel drug therapies that have shown to improve both quality and quantity of life in patients with this very serious illness.
During the ISHLT Meeting, researchers will discuss the results of new trial evidence of drugs including the endothelin antagonists Sitaxentan and Bosentan, prostenoids including Trepostenil and Prostacyclin, and Viagra